Background: Loss of PTEN has been shown to be associated with aggressive behavior of prostate
INTRODUCTION
The use of prostate-specific antigen (PSA) screening for prostate cancer has likely contributed to reductions in cancer-specific mortality (1, 2) , while at the same time over-treatment is a concern for many PSA test-detected cancers (3, 4) . The reason for such a controversy lies in the heterogeneous nature of prostate cancer, of which the clinical behaviors vary greatly (5) (6) (7) (8) . While many tumors grow slowly and would not pose a threat if left untreated, some clinically organ-confined tumors progress rapidly and develop metastasis even after local therapy. Therefore, it is of urgent need and great clinical importance to identify key factors or molecular events that can determine or predict the behaviors of the tumor.
One such marker for prostate cancer is phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a tumor suppressor that negatively regulates the PI3K/Akt pathway (9, 10) .
Loss or inactivation of PTEN, usually leading to constitutive activation of the PI3K/Akt pathway, has been implicated in a number of human malignancies, including prostate cancer (11-13). In animal models, prostate-specific PTEN knockout can lead to tumorigenesis, progression, and metastasis of prostate cancer (14) (15) (16) . In epidemiologic and clinical studies, loss or reduction of PTEN in prostate tumors has been shown to be associated with higher grade (17) (18) (19) (20) , more advanced stages (18, 20) , greater angiogenesis (21) , faster progression to androgen independence (22), and increased risk of recurrent disease (22) (23) (24) (25) . The role of PTEN loss in association with prostate cancer-specific mortality, however, is less clear. Both positive and null findings have been reported (18, 19, 26) . Homozygous deletions or mutations of PTEN gene, resulting in total loss of PTEN activity, occur at relatively low frequencies of 10%-15% in primary prostate cancer (11, 21) . However, a significantly higher proportion of tumors have reduced PTEN protein level (17, 20, 27) , and such reductions may be sufficient to influence prostate cancer survival (24, 26) . 6 formation in mouse models (30, 31) . Several clinical studies reported high IGF1R expression has been detected in human tumor specimens and the expression level correlates with metastasis (32) (33) (34) .
Epidemiologic studies on IGF1 signaling in relation to risk of prostate cancer have nearly exclusively focused on circulating IGF1 and IGF binding proteins (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) . Although some recent findings have been null, the majority of the studies support a positive association between IGF1 and prostate cancer risk.
We hypothesize that reduction or loss of PTEN expression in prostate tumor contributes to cancer progression. Since the PI3K/PTEN/Akt pathway is downstream of IGF1/IGF1R, the effect of PTEN loss may be modified by IGF1 signaling. To test our hypotheses, we examined tumor protein expression of PTEN and IGF1R from specimens of 805 men who were diagnosed with prostate cancer and underwent radical prostatectomy as therapy, and followed them prospectively for cancerspecific mortality or development of distant metastasis. We evaluated whether PTEN protein expression in tumor is related to the risk of lethal prostate cancer, defined by cancer-specific mortality or distant metastasis. We also investigated IGF1R expression in tumor as a potential effect modifier for the association between PTEN expression and lethal prostate cancer risk. The research was approved by the Institutional Review Board at the Harvard School of Public Health and the Partners Health Care.
MATERIALS AND METHODS

Study Population
The men with prostate cancer in this study were participants in the prospective Physicians' Health Study (PHS) and Health Professionals Follow-up Study (HPFS). The PHS was a randomized trial among 29,067 US male physicians ages 40-84 at randomization in the primary prevention of cancer and cardiovascular disease. Participants are sent annual questionnaires to ascertain disease endpoints as well as lifestyle, dietary and medical covariate data as part of the main trial. The HPFS is an ongoing prospective cohort study of 51,529 U.S. male health professionals who were aged 40 to 7 75 years at baseline in 1986. The participants have been sent a questionnaire every 2 years since 1986 to update their information on lifestyle factors, medical history, and disease outcomes.
The PHS and HPFS Prostate Tumor Cohort is a sample of participants for whom we had retrieved archival formalin-fixed, paraffin embedded prostatectomy (95%) and TURP (5%) tumor specimens from these men. The current analysis is based among 804 men (329 from PHS and 475 from HPFS) for whom the first batch of molecular assessment of PTEN expression was completed.
Ascertainment of Outcome
In both the PHS and HPFS cohorts, cases of prostate cancer were identified by self-report, then confirmed by review of medical records and pathology reports. Clinical information, such as tumor stage and PSA at diagnosis, was acquired through a standardized review of medical records.
The cohorts were followed prospectively for cancer and all-cause mortality. Deaths were ascertained through repeated mailings, telephone calls to non-respondents, and searches of the National Death Index. All causes of death were confirmed by extensive review of death certificates and medical records. Follow-up for cancer was >96% complete and for mortality >98% complete. Participants who had prostate cancer were separately followed. Detailed information on treatment and development of metastasis was obtained via additional questionnaires and collection of medical records.
Immunohistochemistry
Angiogenesis. Protein expression of endothelial cell marker CD34 was ascertained on 5 micron sections using the anti-CD34 mouse monoclonal antibody (QBE ND 10 
Statistical Analysis
In the analyses presented here, we used the baseline questionnaire data when the participants entered the original HPFS and PHS studies as baseline for demographic measures.
For each individual, we calculated the minimum, mean, and maximum values for percent area staining and staining intensity of PTEN across the TMA cores for an individual. These values were qualitatively similar; therefore we only presented the analyses using the mean values. We consider the percent area staining, reflecting the percent of tumor tissue with PTEN expression, as the most relevant measure to evaluate the potential role of PTEN in cancer progression. Additionally, we also generated a combined staining score, by multiplying the mean percent staining and the mean staining intensity, to reflect total PTEN expression in the tumor. These two measures were used as continuous variables in the analyses. They were also divided into quartiles according to the cohort distribution. In addition, we created an arbitrary cutoff point for each of these two measures by combining the bottom three quartiles as the low expression group. Less than 32% is considered as low percent staining, and less than 32.25 as low score. We compared clinical characteristics of prostate cancer cases including age at diagnosis, baseline body mass index (BMI), tumor stage, Gleason grade, and PSA at diagnosis, as well as cellular biomarkers for characteristics of angiogenesis (microvessel size and irregularity), apoptosis, and cell proliferation, across quartiles of PTEN expression. We calculated a p-for-trend value from ANOVA for age at diagnosis, baseline BMI, angiogenic characteristics, apoptosis, and cell proliferation across PTEN quartiles. Using the Mantel-Haenszel statistic, we tested whether there is a linear trend for tumor stage, Gleason grade, or PSA at diagnosis across quartiles of PTEN expression.
We employed time-to-event analyses to evaluate the association of PTEN expression on development of lethal prostate cancer (cancer-specific death or development of distant metastasis). Hazard ratios (HR) and 95% confidence intervals (CI) were estimated from the Cox proportional hazard regression models. We adjusted for age at diagnosis (5-year categories), diagnosis era (pre-PSA era: before 1989, peri-PSA era: 1989-1993, PSA era: after 1993), baseline BMI (kg/m 2 , continuous), and baseline smoking status (current, non-current). In additional models, we examined PTEN expression and lethal prostate cancer independent of tumor stage (T1/T2, T3, T4), Gleason score (6 or less, 7-10), and PSA at diagnosis (ng/ml; <4.1, 4.1-9.9, 10 or higher, or missing). The trend tests across quartiles of percent staining and the multiplicative score were performed by assigning median values of these categories and entering these values as continuous terms in the Cox model.
To investigate whether the associations between PTEN expression and lethal prostate cancer risk differ between the HPFS and PHS cohorts, we conducted survival analyses in the HPFS and PHS separately, and calculated the Q statistics, which follows an approximate χ2 distribution with 1 degree of freedom. Due to the absence of heterogeneity, the two cohorts were merged for all analyses.
We assessed whether the association between of PTEN expression and the development of lethal prostate cancer differed by IGF1R expression in a subset of individuals (N=651), who have both the PTEN and IGF1R expression measured. IGF1R expression was measured by a multiplicative score, similar to that of PTEN expression. The top tertile of the IGF1R multiplicative score was arbitrarily defined as high IGF1R expression. We performed stratified survival analyses by the IGF1R multiplicative score to evaluate the associations of percent PTEN staining and PTEN multiplicative staining score and lethal prostate cancer risk. We also generated interaction terms between PTEN expression measures and the IGF1R multiplicative score, and fitted multivariate Cox models with main effect measures and covariates. The significance of the interaction was determined using Wald test to test the beta-coefficients of the cross-product terms.
We evaluated the ability of PTEN and IGF1R expression to predict 10-year survival after diagnosis of prostate cancer using logistic regression, comparing the base model containing only clinical and demographic covariates to the model also containing PTEN and IGF1R expression and their interaction. Area under curve (AUC), net reclassification improvement (NRI), and integrated discrimination index (IDI) were calculated for these two nested models.
All statistical analyses were two-sided and a P-value of less than 0.05 was considered statistically significant. We conducted all analyses using the SAS software (SAS Institute, Inc., Version 9.1, Cary, NC).
RESULTS
The baseline characteristics of the HPFS and PHS Tumor Cohorts are presented in Table 1 .
These two cohorts were demographically and clinically similar. In HPFS, 475 men who were 
The characteristics of prostate cancer cases were compared across quartiles of PTEN expression, as shown in Table 2 . No significant differences in age at cancer diagnosis, baseline BMI, or PSA at diagnosis were observed across quartiles of percent area for PTEN staining. Tumors with lower percent area for PTEN staining were more likely to be advanced stage (P for trend = 0.06) and higher Gleason grade (P for trend = 0.049). The results were similar when PTEN expression was stratified according to the multiplicative staining score (data not shown). Higher expression of PTEN appeared to be associated with more apoptosis in tumor cells (P for trend = 0.002). Such a trend was not present for either characteristics of angiogenesis including microvessel size and irregularity or cell proliferation.
We evaluated the association between PTEN expression in tumor and lethal prostate cancer To examine the potential interaction between PTEN and IGF1R expression, we stratified the study population by IGF1R staining score. As shown in Table 4 significantly predictive of lethal disease, adjusted for both demographic and clinical parameters. A statistically significant trend in risk of lethal prostate cancer was present across the quartiles of PTEN expression (P = 0.01 for percent and P = 0.04 for score). Low percent and low score for PTEN staining were both associated a more-than-10-fold increase in the multivariate HR. However, when the expression of IGF1R protein is high in the tumor, no association between measures of PTEN expression and lethal prostate cancer was observed. A strong negative interaction was observed between PTEN and IGF1R expression (P = 0.03). In additional multivariate survival analyses presented in Figure 1 , we used men with low score for IGF1R staining and high percent of tumor with PTEN staining as the reference group. High score for IGF1R staining alone was associated with an HR of 13.8 (95% CI: 1.7-112.8). Similarly, low percent of tumor with PTEN staining alone was associated with an HR of 11.4 (95% CI: 1.5-84.3). However, combining these two conditions did not confer additional risk for lethal prostate cancer (HR = 12.0, 95% CI: 1.6-90.2).
To assess the ability of PTEN and IGF1R expression to predict 10-year survival after diagnosis of prostate cancer, we compared the base logistic regression model that included (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) . Evidence that high levels of circulating IGF1 significantly increase the risk of total prostate cancer became less than convincing with some recent reports of null findings (37, 41, 43) . However, several studies, including the PHS and HPFS, have shown that IGF1 is more strongly associated with low-grade prostate cancer (35, 40, 45) . A recent pooled analysis of individual patient data from 12 prospective studies yielded a significantly elevated risk for prostate cancer, comparing the highest vs. the lowest quintiles of the serum IGF-1 concentration (46). This increased risk became more pronounced when the analysis was restricted to low-grade prostate tumors, suggesting poorly-differentiated tumors, which are more autonomous, are less sensitive to the stimulus of IGF1. Such reduced dependence of IGF1 may be the result of alterations in expression of the downstream signaling pathway molecules, including those in the PI3K/Akt pathway. As described previously, loss of PTEN is strongly associated with high grade prostate tumor. We also found that lower PTEN levels were significantly associated with higher Gleason grade. Thus our finding that higher levels of IGF1R expression in tumor was related to lethal prostate cancer when PTEN level was high whereas lower PTEN was related to lethal outcome regardless IGF1R further support the notion that poorly-differentiated tumors are less sensitive to IGF1/IGF1R.
In addition to IGF1R, IGF1 also binds to and activate insulin receptor (IR) at a weaker affinity (29) . However, no interaction between PTEN and IR expression was present in our study population (data not shown), suggesting the interaction between PTEN and IGF1R is specific to the IGF1/PI3K/Akt signaling cascade and the involvement of insulin signaling may be limited.
There are potential limitations in our study to be considered. First, the PHS and HPFS Tumor Cohort consists of physicians and health professionals, are mainly Caucasian, and have relatively high socio-economic status. Thus it is not a random sample of the general population. This may limit the generalizability of the results, though the validity of the study is not undermined. We may be able to gain insights into the underlying biological mechanism through which reduced PTEN expression may promote prostate cancer progression. Secondly, we have relatively few deaths or distant metastases from prostate cancer considering our large sample size. However, despite the small 
expression. Thirdly, the tumor specimens were obtained only when men underwent prostatectomy or TURP as curative treatment for their cancer. These are largely localized, organ-confined tumors.
Those who were diagnosed with more advanced cancers may be ineligible for surgical intervention and have undergone hormonal, radiation therapy, or chemotherapy. Since loss or reduction of PTEN is generally regarded as a late event in prostatic tumorigenesis, and is associated with more malignant tumors and worse prognosis, it is likely that our analysis underestimates the role of PTEN expression in relation to prostate cancer mortality. The use of tumor blocks may generate certain heterogeneity for these tumors were diagnosed at different times, and fixed and processed in different pathological labs. Last, the presence of missing data such as PSA at diagnosis and baseline smoking status can lead to residual confounding by these factors. Uncontrolled confounding by unknown or unmeasured factors can not be ruled out either.
The prospective study design with long-term and complete follow-up adds to the strength of our analysis. Clinical characteristics of the cancers were systematically extracted from medical records in a standardized format. The study pathologists reviewed the records and provided uniform Gleason grades for all cases. These approaches should contribute to reduction in measurement errors. Additionally, we used cause-specific death and distant metastasis as the outcome, which are the most clinically relevant endpoints for prostate cancer.
In conclusion, low levels of PTEN protein are associated with an increased risk of lethal prostate cancer. This association is strongly modified by IGF1R expression in the tumor. Our results reinforce the idea that the PI3K/PTEN/Akt pathway plays a critical role in prostate cancer survival.
PTEN and IGF1R are eligible independent predictors for prognosis. Their interaction may shine light on the complex picture of IGF axis in prostate tumorigenesis and cancer progression. 
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